Cemiplimab
About
Therapy type: Immunotherapy
Therapy strategy: PD-1/PD-L1 inhibition
Mappings
NCI Thesaurus: Cemiplimab (ncit:C121540)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR | Non-Small Cell Lung Cancer | Cemiplimab | |
| Sensitivity (+) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Cemiplimab | |
| Sensitivity (+) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed |